title: Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
abstract: We studied the removal of aluminum (Al), iron (Fe), copper (Cu), lead (Pb) and zinc (Zn) with continuous ambulatory peritoneal dialysis, before and after desferrioxamine B (DFO) administration (2 g intravenously) in two patients with chronic renal failure and Al-related osteopathy. Both patients had 4 peritoneal dialysis exchanges (2 liters each) per day. Blood concentrations of Al increased 413% (patient A) and 190% (patient B) after DFO. Patient B had a 15% increase in Fe; other metals remained unchanged. Dialysate efflux Al concentrations had peak post-DFO increments of 761% and 840% in patients 1 and 2, respectively. Peak post-DFO increments in Fe dialysate concentration were 342% and 89.5% in the respective patients. Dialysate/plasma (D/P) concentration ratios of Al increased from pre-DFO levels (mean +/- SEM) of 0.370 +/- 0.048 to 0.523 +/- 0.061 after DFO; similarly, Fe D/P ratios increased from 0.259 +/- 0.053 to 0.446 +/- 0.075 with DFO therapy. These results indicate an increase in the ultrafiltrable proportion of Al and Fe in plasma after DFO administration. During 3 days after DFO, patient 1 had a total removal of Al and Fe of 2.9 mg and 4.9 mg, respectively. Metal removal in patient 2 was 7.6 mg of Al and 2.7 mg of Fe. Peritoneal extraction of other trace metals was minor.
authors.affiliation: Analytical Instrumentation Laboratory, Faculty of Sciences, Universidad del Zulia, Maracaibo, Venezuela.
authors.forename: J A
authors.initials: JA
authors.lastname: Navarro
authors.forename: V A
authors.initials: VA
authors.lastname: Granadillo
authors.forename: B
authors.initials: B
authors.lastname: Rodríguez-Iturbe
authors.forename: R
authors.initials: R
authors.lastname: García
authors.forename: O
authors.initials: O
authors.lastname: Salgado
authors.forename: R A
authors.initials: RA
authors.lastname: Romero
mesh_terms: D000328:Adult; D000535:Aluminum / Q000009:adverse effects; D015913:Chelation Therapy; D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D010018:Osteomalacia / Q000139:chemically induced / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D014131:Trace Elements
chemical_list: D014131:Trace Elements; D000535:Aluminum; D003676:Deferoxamine